Pulmonary Cryptococcosis in the Setting of Tofacitinib Therapy for Psoriasis.
Tofacitinib is a novel drug that inhibits the JAK-STAT signaling pathway. It has been approved for the treatment of psoriatic arthritis and it is under investigation for the treatment of psoriasis and other inflammatory disorders. We report a case of pulmonary cryptococcosis in an otherwise immunocompetent patient taking tofacitinib for psoriasis. We hypothesized that tofacitinib contributed to this infection through inhibition of cytokines required for differentiation of T cells and suppression of macrophage activation. As dermatologists begin to use this drug they should be aware of the potential for cryptococcocal infection, because delay of diagnosis may increase the risk of a life-threatening outcome.
Lucia
L
Seminario-Vidal
Wendy
W
Cantrell
Boni E
BE
Elewski
D000368:Aged; D003453:Cryptococcosis / Q000139:chemically induced*; D006801:Humans; D008171:Lung Diseases / Q000139:chemically induced* / Q000382:microbiology; D008297:Male; D010880:Piperidines / Q000009:adverse effects*; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011565:Psoriasis / Q000188:drug therapy*; D011743:Pyrimidines / Q000009:adverse effects*; D011758:Pyrroles / Q000009:adverse effects*
D010880:Piperidines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D011758:Pyrroles; C479163:tofacitinib